Sun Pharma Research shows licensing spark; Aurobindo plans $140.8M in FY capex;

> India's Sun Pharma Advanced Research licenses xelpros eye drops to Sun Pharmaceutical Industries for an upfront payment of $3 million and potential milestone payments of $16 million. Release (PDF)

> Sun Pharma Advanced Research also said it aims to license and commercialize epilepsy drug Elepsia XR in the U.S. by the second-half of the financial year. Report

> Tokyo-listed biopharmaceutical firm PeptiDream said it received an undisclosed payment from Bristol-Myers Squibb ($BMY) for an unidentified candidate reaching the exploratory clinical development stage in a license agreement that extends back to October 2010. Release

> NYSE-listed Aoxing Pharmaceutical ($AXN) said it has been granted China FDA approval to produce a narcotic pain reliever, tilidine hydrochloride, in China. Report

> India's Aurobindo Pharma plans to spend $140.8 million in the financial year on expansion, clinical trials and product filings, Managing Director N. Govindarajan said in an analyst call. Report

> Piramal Imaging said it has presented new data on Florbetaben in detecting beta-amyloid plaque in patients with suspected Alzheimer's disease. Release

> The Crime Investigation Department of India's Telangana state has registered a case against a subsidiary of drug maker Abbott India over alleged smuggling of cough syrup "Phensedyl" to Bangladesh. Report

> AstraZeneca Pharma India ($AZN) plans to launch Forxiga in India to treat Type 2 diabetes. Release (PDF)

And Finally... Glenmark Pharmaceuticals said it won final U.S. FDA approval for calcipotriene cream and will start shipments immediately. Release (PDF)